<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>FDA appears to pause controversial speedy review program, complete response letter disclosures — Live Feed</title><link>https://www.live-feeds.com/feed/fda-appears-to-pause-controversial-speedy-review-program-complete-response-letter-disclosures</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/fda-appears-to-pause-controversial-speedy-review-program-complete-response-letter-disclosures/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>FDA shelves commissioner's priority review voucher program</title><link>https://www.live-feeds.com/feed/fda-appears-to-pause-controversial-speedy-review-program-complete-response-letter-disclosures</link><guid isPermaLink="false">https://www.live-feeds.com/feed/fda-appears-to-pause-controversial-speedy-review-program-complete-response-letter-disclosures#u203503</guid><pubDate>Mon, 16 Nov 2026 05:57:00 +0000</pubDate><description>The U.S. Food and Drug Administration has paused its controversial commissioner&amp;#039;s priority review voucher program, according to multiple reports citing sources. The program, championed by Commissioner Marty Makary, would have granted vouchers for expedited drug reviews. Reports indicate the decision comes ahead of a Senate vote on the nomination of Dr. Dave Overton. The pause effectively halts a mechanism that could have accelerated approvals for certain drug candidates.Why it mattersThe commissioner&amp;#039;s voucher program drew criticism for potentially bypassing standard review rigor and</description></item>
</channel></rss>